The European Commission has approved a new subcutaneous (under-the-skin) formulation of Sarclisa (isatuximab), a treatment for multiple myeloma that was previously available in…
Myeloma
I catch glimpses of him in the bathroom mirror at 3 a.m. He is thinner than I remember. His eyes look older, even though the…
Treatment with a regimen based on the experimental therapy mezigdomide reduced the risk of disease progression or death by more than 50% compared with standard…
I don’t think it’s any secret that I have a thing for heroes, super-powered or otherwise. Just look at the artwork for this column!…
One day last month, my mum laughed out loud at a silly joke on the comedy show she was watching on TV. The sound filled…
For World Blood Cancer Day this May 28 — a day when advocates around the globe join forces to raise awareness…
The kitchen counter used to mean Sunday mornings. I would stand there slicing up tomatoes, onions, and other vegetables. And as the sharp smell rose,…
A Phase 1 clinical trial testing the experimental therapy KLN-1010 in people with relapsed or refractory multiple myeloma has begun treating patients in the…
I used to say if I needed to take a pill every day to survive, I’d be dead in a week. So it felt like…
Some mornings, I slip into borrowed strength the way other people put on a coat. Others might wonder why I do this. After all, I’m…
Recent Posts
- EU approves under-the-skin Sarclisa for multiple myeloma
- FDA approves dissolving formulation of leukemia drug nilotinib
- Collaboration to test 2 pancreatic cancer treatments in combination
- The caregiver’s shadow self: Who I am becoming in the margins
- Trial data back glioblastoma treatment’s potential to extend survival
